



**Biocon Limited**

20th KM Hosur Road  
Electronics City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423  
CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

Letter No: 2017/SEC/MARCH/008

Date: March 03, 2017

The Manager,  
Dept. of Corporate Services- Listing,  
The Bombay Stock Exchange Limited,  
P J Tower, Dalal Street,  
Mumbai – 400 001.

The Manager- Listing Department,  
National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra – East,  
Mumbai – 400051.

BSE – Scrip code - **532523**

NSE – Scrip code - **BIOCON**

Dear Sir,

**Sub: Biocon's statement in response to Delhi High Court Interim Order**

Please find enclosed the company's statement in response to Delhi High Court interim order permitting Biocon to manufacture and sell its biosimilar trastuzumab, CANMAb™

Request you to take on record the same.

Thanking you,

Yours faithfully,  
For Biocon Limited,

Authorised Signatory



## **BIOCON STATEMENT**

**Trastuzumab: Delhi High Court Interim Order: March 3, 2017**

“We welcome the Delhi High Court interim order passed today permitting Biocon to manufacture and sell its biosimilar trastuzumab, CANMAb™ without any restrictions for all three indications namely Her2 Metastatic Breast Cancer (MBC), Early Breast Cancer (EBC) and Metastatic Gastric Cancer (MGC). The Division Bench not only has stayed the operation of the order of April 2016, but also pronounced in court that Biocon can use the Package Insert for all three indications including the publically available data of the reference product therein as it has been approved by the Drugs Controller General of India (DCGI).

We see this as a significant positive development which will pave the way for greater access to affordable biosimilar trastuzumab for cancer patients in India. Biocon’s CANMAb™ has been developed as per existing Indian biosimilar guidelines and has been introduced in the market in 2014, post clinical studies and necessary regulatory approvals. Since then it has been providing an affordable alternative to Her2 positive breast cancer patients in India.”

**-Company Spokesperson**

